42 terminated. 42 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 42 | Terminated 42 |
Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of NVX-CoV2705 NVX-CoV2705, Placebo - COVID-19, Sars-CoV-2 Infection | Phase 4 | Terminated | Novavax | 6500 | 2025-11-20 | 2026-10-23 |
| The Duration of Antibiotic Therapy for Early (DATE) Ventilator Associated Pneumonia (VAP): 4 vs. 7 Days Standard of Care Antibiotic Therapy - Ventilator Associated Pneumonia | Phase 4 | Terminated | University of Miami | 27 | 2023-05-08 | 2026-01-16 |
| Addressing Cognitive Fog in Long-COVID-19 Patients Digital cognitive behavioral intervention-RxWell, Amphetamine-Dextroamphetamine - Cognitive Impairment, Long COVID | Phase 4 | Terminated | Eva Szigethy | 7 | 2023-04-04 | 2024-07-22 |
| Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation Ceftolozane / Tazobactam Injection - Pneumonia, Hematologic Malignancy | Phase 4 | Terminated | Weill Medical College of Cornell University | 17 | 2023-01-10 | 2026-01-21 |
| Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis Imipenem/Cilastatin/Relebactam - Cystic Fibrosis, Pneumonia, Bacterial | Phase 4 | Terminated | Hartford Hospital | 4 | 2023-01-03 | 2024-12-17 |
| Endothelial Protection in Convalescent COVID-19 Patients Sulodexide - Endothelial Dysfunction, Inflammation | Phase 4 | Terminated | Pirogov Russian National Research Medical University | 2 | 2022-04-01 | 2025-06-13 |
| A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults AZD1222 - COVID-19, SARS-CoV-2 | Phase 4 | Terminated | AstraZeneca | 34 | 2022-01-31 | 2025-01-27 |
| BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia Cefepime, Meropenem, or Piperacillin/Tazobactam - Pneumonia | Phase 4 | Terminated | University of Florida | 35 | 2021-12-17 | 2023-12-12 |
| COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 Spikevax, Comirnaty, Spikevax bivalent Original/Omicron BA.1 - Cancer | Phase 4 | Terminated | Jules Bordet Institute | 152 | 2021-12-01 | 2024-01-17 |
| Early Antibiotics After Aspiration in ICU Patients Ceftriaxone, Amoxicillin clavulanic acid, Cefepime - Aspiration, Aspiration Pneumonia | Phase 4 | Terminated | UConn Health | 5 | 2021-11-30 | 2025-12-30 |
| Echinaforce COVID-19 Shedding Study Echinaforce Forte tablets, Echinaforce Chewable tablets, Echinaforce tincture - COVID-19 Respiratory Infection, SARS-CoV2 Infection | Phase 4 | Terminated | A. Vogel AG | 40 | 2021-11-15 | 2024-08-06 |
| Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen COVID-19 Vaccine Janssen (Ad26.COV2-S) - Healthy Volunteers | Phase 4 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 27 | 2021-09-20 | 2025-02-10 |
| A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate - Relapsing Multiple Sclerosis (RMS) | Phase 4 | Terminated | Novartis Pharmaceuticals | 24 | 2021-06-10 | 2025-05-16 |
| UPMC OPTIMISE-C19 Trial, a COVID-19 Study Lilly Bamlanivimab, Regeneron Casirivimab + Imdevimab, Lilly Bamlanivimab + Etesevimab - Covid19 | Phase 4 | Terminated | Erin McCreary | 4571 | 2021-03-10 | 2023-06-15 |
| Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 Apixaban 2.5 MG, Placebo - Covid19, Thrombosis | Phase 4 | Terminated | Brazilian Clinical Research Institute | 411 | 2021-03-04 | 2022-08-25 |
| COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study Dexamethasone - Covid19, Corona Virus Infection | Phase 4 | Terminated | General Practitioners Research Institute | 17 | 2021-02-16 | 2021-05-11 |
| Treatment of Nosocomial COVID-19 Anti-SARS-CoV-2 mAb - Covid19, Nosocomial Infection | Phase 4 | Terminated | University of Calgary | 46 | 2021-02-12 | 2023-04-19 |
| At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19 bamlanivimab - Covid19 | Phase 4 | Terminated | Daniel Griffin | 139 | 2021-01-04 | 2022-03-18 |
| Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) Enoxaparin sodium, Unfractionated heparin, Fondapariniux - COVID-19 | Phase 4 | Terminated | Weill Medical College of Cornell University | 14 | 2020-10-13 | 2023-09-21 |
| Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Sodium bicarbonate, Standard of Care - COVID, Coronavirus | Phase 4 | Terminated | West Virginia University | 3 | 2020-10-05 | 2023-12-22 |
Showing 20 of 42. Sign in to see all of them.
COVID-19 (23) · Coronavirus Infections (4) · Community-Acquired Pneumonia (3) · Pneumonia, Ventilator-Associated (3) · Respiratory Distress Syndrome (3) · Respiratory Tract Infections (3) · Bacteremia (2) · Pneumonia, Aspiration (2) · Thrombosis (2) · Acute Kidney Injury (1) · Acute Lung Injury (1) · Asymptomatic Diseases (1) · Atherosclerosis (1) · Bronchial Spasm (1)
Infections (42) · Respiratory Tract Diseases (42) · Lung Diseases (40) · Respiratory Tract Infections (39) · Coronaviridae Infections (24) · Nidovirales Infections (24) · Pneumonia, Viral (24) · RNA Virus Infections (24) · Virus Diseases (24) · Coronavirus Infections (20) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12) · Disease Attributes (7) · Bacterial Infections and Mycoses (5)
Chloroquine (3) · Dexamethasone (3) · Azithromycin (2) · Cefepime (2) · Ceftriaxone (2) · Heparin (2) · Levofloxacin (2) · Propofol (2) · Vancomycin (2) · bamlanivimab (2) · sotrovimab (2) · telithromycin (2) · 2019-nCoV Vaccine mRNA-1273 (1) · Ad26COVS1 (1) · Adderall (1)
Sanofi (3) · AstraZeneca (2) · Government of Punjab, Specialized Healthcare and Medical Education Department (2) · Weill Medical College of Cornell University (2) · A. Vogel AG (1) · Beth Israel Deaconess Medical Center (1) · Beth Israel Medical Center (1) · Brazilian Clinical Research Institute (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Chinese University of Hong Kong (1) · Daniel Griffin (1) · EASL - CLIF Consortium (1) · Erin McCreary (1) · Eva Szigethy (1) · Frederick Health (1)
United States (21) · Netherlands (4) · Spain (4) · Brazil (2) · Canada (2) · France (2) · Pakistan (2) · Belgium (1) · Bulgaria (1) · Germany (1) · Hong Kong (1) · Russia (1) · Thailand (1) · Tunisia (1) · Ukraine (1)
Agustin Albillos (1) · Aide McCormick (1) · Alain Tremblay (1) · Alexander Gerbes (1) · Ammar Sarwar, MD (1) · Andrea de Gottardi (1) · Ankit Sakhuja, MD (1) · Brandon Oto (1) · Carlo Alessandria (1) · Charles Peloquin (1) · Dan Griffin, MD, PHD (1) · David S Seres, MD (1) · David T Huang, MD, MPH (1)
PMID 34473343, PMID 35244208, PMID 37591523, PMID 27449641, PMID 30603378, PMID 31394283, PMID 32043986, PMID 32512291, PMID 32799933, PMID 33446608, PMID 33502773, PMID 34034784, PMID 35697146, PMID 35713300, PMID 35834252, PMID 37018790, PMID 37223666